Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine.

Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine.
复制标题

DOI:
10.1038/s41589-022-01098-0
复制
发表时间:
2022-12
影响因子:
14.8
通讯作者:
Cravatt BF
Cravatt BF
中科院分区:
生物学1区
文献类型:
--
作者:
Kavanagh ME;Horning BD;Khattri R;Roy N;Lu JP;Whitby LR;Ye E;Brannon JC;Parker A;Chick JM;Eissler CL;Wong AJ;Rodriguez JL;Rodiles S;Masuda K;Teijaro JR;Simon GM;Patricelli MP;Cravatt BF

文献摘要

参考文献

被引文献

相似文献

Janus酪氨酸激酶(JAK)家族是一类非受体酪氨酸激酶,包括JAK1、JAK2、JAK3和TYK2四种异构体,负责多种细胞因子受体下游的信号转导。JAK抑制剂已经成为治疗免疫性肿瘤疾病的重要疗法,但它们的使用受到不良副作用的限制,这些副作用被认为是由于较差的异构体选择性而产生的,这是靶向ATP结合的激酶口袋的抑制剂的常见挑战。在这里,我们描述了在JAK1(C817)和TYK2(C838)的非催化假激酶结构域中存在但在JAK2或JAK3中不存在的可药物变构半胱氨酸的化学蛋白质组学发现。选择性地结合这个位点的亲电化合物阻止JAK1依赖的反式磷酸化和细胞因子信号转导,同时似乎在很大程度上充当TYK2的“沉默”配体。重要的是,变构JAK1抑制剂不会损害JAK2依赖的细胞因子信号转导,并且在表达C817A JAK1突变的细胞中是无效的。因此,我们的发现揭示了一种以前所未有的异构体选择性抑制JAK1的变构方法。
The Janus tyrosine kinase (JAK) family of non-receptor tyrosine kinases includes four isoforms (JAK1, JAK2, JAK3, and TYK2) and is responsible for signal transduction downstream of diverse cytokine receptors. JAK inhibitors have emerged as important therapies for immun(onc)ological disorders, but their use is limited by undesirable side effects presumed to arise from poor isoform selectivity, a common challenge for inhibitors targeting the ATP-binding pocket of kinases. Here we describe the chemical proteomic discovery of a druggable allosteric cysteine present in the non-catalytic pseudokinase domain of JAK1 (C817) and TYK2 (C838), but absent from JAK2 or JAK3. Electrophilic compounds selectively engaging this site block JAK1-dependent trans-phosphorylation and cytokine signaling, while appearing to act largely as ‘silent’ ligands for TYK2. Importantly, the allosteric JAK1 inhibitors do not impair JAK2-dependent cytokine signaling and are inactive in cells expressing a C817A JAK1 mutant. Our findings thus reveal an allosteric approach for inhibiting JAK1 with unprecedented isoform selectivity.
DOI: 10.1016/j.stem.2017.08.011
发表时间: 2017-10-05
期刊: Cell stem cell
影响因子: 23.9
作者:
Kleppe M;Spitzer MH;Li S;Hill CE;Dong L;Papalexi E;De Groote S;Bowman RL;Keller M;Koppikar P;Rapaport FT;Teruya-Feldstein J;Gandara J;Mason CE;Nolan GP;Levine RL
通讯作者: Levine RL
DOI: 10.1016/j.chembiol.2011.01.012
发表时间: 2011-03-25
影响因子: --
作者:
Haan, Claude;Rolvering, Catherine;Zerwes, Hans-Guenter
通讯作者: Zerwes, Hans-Guenter
DOI: 10.1158/0008-5472.can-04-4316
发表时间: 2005-04-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Dunn, GP;Sheehan, KCF;Schreiber, RD
通讯作者: Schreiber, RD
DOI: 10.1016/j.cell.2017.08.051
发表时间: 2017-10-19
期刊: Cell
影响因子: 64.5
作者:
Bar-Peled L;Kemper EK;Suciu RM;Vinogradova EV;Backus KM;Horning BD;Paul TA;Ichu TA;Svensson RU;Olucha J;Chang MW;Kok BP;Zhu Z;Ihle NT;Dix MM;Jiang P;Hayward MM;Saez E;Shaw RJ;Cravatt BF
通讯作者: Cravatt BF
DOI: 10.1038/nchembio760
发表时间: 2006-02-01
影响因子: 14.8
作者:
Adrián, FJ;Ding, Q;Gray, NS
通讯作者: Gray, NS